WallStreetZenWallStreetZen

NASDAQ: INCR
Intercure Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their INCR stock forecasts and price targets.

Forecast return on equity

Is INCR forecast to generate an efficient return?

Company
60.56%
Industry
193.25%
Market
260.67%
INCR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INCR forecast to generate an efficient return on assets?

Company
34.73%
Industry
108.54%
INCR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INCR earnings per share forecast

What is INCR's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.59
Avg 2 year Forecast
$1.70

INCR revenue forecast

What is INCR's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$404.9M+462.96%
Avg 2 year Forecast
$574.0M+698%
INCR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

INCR revenue growth forecast

How is INCR forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
441.31%
Industry
3,365.85%
Market
1,339.67%
INCR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
INCR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

INCR vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
INCR$1.51N/AN/A
BGM$9.34N/AN/A
ASRT$0.82$3.00+265.85%Buy
CPIX$3.49N/AN/A
QNTM$13.90N/AN/A
View Top Pharmaceutical Stocks

Intercure Stock Forecast FAQ

What is INCR's earnings growth forecast for 2025-2026?

(NASDAQ: INCR) Intercure's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 10,890.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,785.55%.

Intercure's earnings in 2025 is -$21,825,230.On average, 3 Wall Street analysts forecast INCR's earnings for 2025 to be $27,901,461, with the lowest INCR earnings forecast at $26,807,286, and the highest INCR earnings forecast at $28,722,092.

In 2026, INCR is forecast to generate $80,336,965 in earnings, with the lowest earnings forecast at $77,186,496 and the highest earnings forecast at $82,699,817.

If you're new to stock investing, here's how to buy Intercure stock.

What is INCR's revenue growth forecast for 2025-2026?

(NASDAQ: INCR) Intercure's forecast annual revenue growth rate of 441.31% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3,365.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,339.67%.

Intercure's revenue in 2025 is $74,807,076.On average, 3 Wall Street analysts forecast INCR's revenue for 2025 to be $19,098,069,002, with the lowest INCR revenue forecast at $18,349,125,120, and the highest INCR revenue forecast at $19,659,776,914.

In 2026, INCR is forecast to generate $27,071,397,262 in revenue, with the lowest revenue forecast at $26,009,764,592 and the highest revenue forecast at $27,867,503,857.

What is INCR's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: INCR) forecast ROA is 34.73%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 108.54%.

What is INCR's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: INCR) Intercure's current Earnings Per Share (EPS) is -$0.47. On average, analysts forecast that INCR's EPS will be $0.59 for 2025, with the lowest EPS forecast at $0.57, and the highest EPS forecast at $0.61. In 2026, INCR's EPS is forecast to hit $1.70 (min: $1.64, max: $1.75).

What is INCR's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: INCR) forecast ROE is 60.56%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.